1. NMS-173, a potent, covalent second generation IDH1/IDH2 inhibitor. (October 2022) Authors: Magnaghi, P.; Casuscelli, F.; Ardini, E.; Parazzoli, A.; Troiani, S.; Valsasina, B.; Texido, G.; Casale, E.; Avanzi, N.; Orsini, P.; Nuvoloni, S.; Salom, B.; Lombardi Borgia, A.; Salsi, E.; Saturno, G.S.; Re Depaolini, S.; Stellato, C.; Montagnoli, A.; Galvani, A.; Isacchi, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapies. (December 2016) Authors: Ardini, E.; Lombardi Borgia, A.; Texido, G.; Alzani, R.; Avanzi, N.; Amboldi, N.; Cribioli, S.; Mancini, L.; Casero, D.; Pastori, W.; Montemartini, M.; Montagnoli, A.; Donati, D.; Galvani, A.; Isacchi, A.; Ciomei, M. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗